Issued 2026-09-25 at $57.43 · now $57.43 (2026-09-25, +0.0% since)
Based on its own history, a month from the 2026-09-25 close, TGTX has typically landed between $40.52 and $85.50 — a range of −29.4% to +48.9% from the issuance price $57.43.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
4,092 overlapping 1 month windows · 2010-05-03 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.
The cone is anchored at the 2026-09-25 issuance close ($57.43) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where TGTX has typically landed a month from the 2026-09-25 close of $57.43 — the range is history, not a prediction.
- now $57.43 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $57.68 (+0.4%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $49.35–$66.01
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $40.52–$85.5
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2012-02-17 | −76.7% | −76.7% | +0.0% |
| 2012-02-10 | −75.0% | −75.0% | +7.5% |
| 2012-02-09 | −71.4% | −71.4% | +22.9% |
| 3 best | |||
| 2012-01-06 | +1891.2% | +0.0% | +1891.2% |
| 2012-01-05 | +1642.5% | +0.0% | +1642.5% |
| 2012-01-04 | +1517.7% | +0.0% | +1517.7% |
4,092 overlapping windows · 2010-05-03 – 2026-09-25 · not cherry-picked
Pending catalysts
- 2026-10-31 — Trial primary completion: Phase 3 primary completion: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) (source, as of 2026-08-14)
- 2027-05-30 — Trial primary completion: Phase 2 primary completion: A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) (source, as of 2026-08-14)
- 2027-12-01 — Trial primary completion: Phase 3 primary completion: Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab (source, as of 2026-08-14)
- 2028-07-01 — Trial primary completion: Phase 2 primary completion: A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) (source, as of 2026-08-14)
- 2028-12-01 — Trial primary completion: Phase 2 primary completion: Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia (source, as of 2026-08-14)
- 2030-01-01 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (source, as of 2026-08-14)
- 2032-05-31 — Trial primary completion: Phase 3 primary completion: An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~17 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-10 | Charney Laurence N | director | Sale | 5,000 @ $54.96 | $275K | −2.9% of holding | not yet — horizon still open | not yet — horizon still open | 168,640 | Form 4 · filed 4 days after the trade |
| 2025-11-24 | Echelard Yann | director | Sale | 5,000 @ $32.57 | $163K | −2.2% of holding | −6.5% | +7.7% | 223,816 | Form 4 · filed 1 day after the trade |
| 2025-09-11 | Lonial Sagar | director | Sale | 20,852 @ $32.24 | $672K | −18.1% of holding | +4.4% | −15.2% | 94,061 | Form 4 · filed 1 day after the trade |
| 2025-06-13 | Echelard Yann | director | Sale | 10,000 @ $36.94 | $369K | −4.2% of holding | +3.0% | −27.8% | 228,816 | Form 4 · filed 3 days after the trade |
| 2025-01-06 | Power Sean A | officer | Sale | 10,021 @ $28.53 | $286K | −1.5% of holding | +17.8% | +28.8% | 660,611 | Form 4 · filed 1 day after the trade |
| 2025-01-03 | Power Sean A | officer | Sale | 11,337 @ $30.29 | $343K | −1.7% of holding | +8.3% | +20.1% | 670,632 | Form 4 · filed 4 days after the trade |
| 2024-11-11 | Charney Laurence N | director | Sale | 25,000 @ $30.20 | $755K | −10.5% of holding | +1.5% | +10.0% | 212,479 | Form 4 · filed 1 day after the trade |
| 2024-11-11 | Lonial Sagar | director | Sale | 5,000 @ $30.44 | $152K | −4.8% of holding | +1.5% | +10.0% | 100,195 | Form 4 · filed 1 day after the trade |
| 2024-11-05 | Echelard Yann | director | Sale | 20,000 @ $24.48 | $490K | −8.2% of holding | +24.9% | +31.6% | 224,098 | Form 4 · filed 2 days after the trade |
| 2024-06-20 | Lonial Sagar | director | Sale | 16,348 @ $16.87 | $276K | −13.5% of holding | +18.7% | +75.1% | 105,195 | Form 4 · filed same day |
| 2024-06-17 | Lonial Sagar | director | Sale | 9,585 @ $16.39 | $157K | −8.8% of holding | +26.8% | +96.0% | 99,293 | Form 4 · filed 3 days after the trade |
| 2024-03-13 | Lonial Sagar | director | Sale | 5,000 @ $15.94 | $80K | −4.4% of holding | −9.3% | +38.4% | 108,878 | Form 4 · filed 2 days after the trade |
| 2024-03-12 | Charney Laurence N | director | Sale | 22,000 @ $15.97 | $351K | −9.3% of holding | −7.4% | +37.7% | 215,229 | Form 4 · filed 1 day after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
29 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-07 | Charney Laurence N | director | Gift | 500 | 174,090 | Form 4 |
| 2026-08-07 | Charney Laurence N | director | Gift | 450 | 173,640 | Form 4 |
| 2026-08-06 | Charney Laurence N | director | Gift | 5,100 | 174,590 | Form 4 |
| 2026-06-11 | Echelard Yann | director | Award / grant | 8,325 | 8,325 | Form 4 |
| 2026-06-11 | HUME DANIEL | director | Award / grant | 8,325 | 8,325 | Form 4 |
| 2026-06-11 | Hoberman Kenneth | director | Award / grant | 8,325 | 8,325 | Form 4 |
| 2026-06-11 | Lonial Sagar | director | Award / grant | 8,325 | 8,325 | Form 4 |
| 2026-06-11 | Charney Laurence N | director | Award / grant | 8,325 | 8,325 | Form 4 |
| 2026-01-29 | Charney Laurence N | director | Gift | 13,197 | 179,690 | Form 4 |
| 2026-01-28 | Charney Laurence N | director | Gift | 30,000 | 192,887 | Form 4 |
| 2026-01-08 | Power Sean A | officer | Award / grant | 90,000 | 798,111 | Form 4 |
| 2026-01-08 | WEISS MICHAEL S | director | Award / grant | 622,000 | 9,778,086 | Form 4 |
| 2025-11-05 | WEISS MICHAEL S | director | Gift | 803,717 | 9,156,086 | Form 4 |
| 2025-11-05 | WEISS MICHAEL S | director | Gift | 3,865,126 | 9,959,803 | Form 4 |
| 2025-06-12 | Lonial Sagar | director | Award / grant | 14,718 | 114,913 | Form 4 |
| 2025-06-12 | Charney Laurence N | director | Award / grant | 21,408 | 222,887 | Form 4 |
| 2025-06-12 | Echelard Yann | director | Award / grant | 14,718 | 238,816 | Form 4 |
| 2025-06-12 | Hoberman Kenneth | director | Award / grant | 14,718 | 279,653 | Form 4 |
| 2025-06-12 | HUME DANIEL | director | Award / grant | 14,718 | 192,748 | Form 4 |
| 2025-03-17 | HUME DANIEL | director | Gift | 62,459 | 178,030 | Form 4 |
| 2025-03-10 | Charney Laurence N | director | Gift | 6,000 | 201,479 | Form 4 |
| 2025-01-29 | WEISS MICHAEL S | director | Award / grant | 750,000 | 13,824,929 | Form 4 |
| 2025-01-29 | Power Sean A | officer | Award / grant | 87,500 | 708,111 | Form 4 |
| 2024-11-12 | Charney Laurence N | director | Gift | 5,000 | 207,479 | Form 4 |
| 2024-06-19 | Lonial Sagar | director | Award / grant | 22,250 | 121,543 | Form 4 |
| 2024-06-19 | Hoberman Kenneth | director | Award / grant | 22,250 | 264,935 | Form 4 |
| 2024-06-19 | HUME DANIEL | director | Award / grant | 22,250 | 240,489 | Form 4 |
| 2024-06-19 | Charney Laurence N | director | Award / grant | 22,250 | 237,479 | Form 4 |
| 2024-06-19 | Echelard Yann | director | Award / grant | 22,250 | 244,098 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.